Axsome Therapeutics Unveils New Sleep Disorder Data at SLEEP 2026
Event summary
- Axsome Therapeutics presented new data on AXS-12 and solriamfetol at SLEEP 2026, held June 14-17, 2026 in Baltimore.
- Three poster presentations detailed cognitive outcomes, symptom burden, and quality of life in narcolepsy patients.
- Lead authors included Bruce Corser MD, Ellen Wertmer, and Michael Thorpy MD.
- AXS-12 data came from the Phase 3 ENCORE trial in narcolepsy with cataplexy.
- Solriamfetol analysis focused on excessive daytime sleepiness in narcolepsy and OSA.
The big picture
Axsome's SLEEP 2026 presentations highlight its push to expand in the sleep disorder market, complementing its existing portfolio of CNS treatments. The focus on narcolepsy with cataplexy and excessive daytime sleepiness positions the company to compete with established players in a segment with significant unmet needs. Success here could diversify Axsome's revenue streams beyond its current approved indications.
What we're watching
- Clinical Validation
- Whether AXS-12 Phase 3 data will support regulatory approval and differentiate it in the narcolepsy market.
- Market Positioning
- How solriamfetol's expanded data may strengthen its position against competitors in sleep disorder treatments.
- Commercial Strategy
- The pace at which Axsome can translate clinical data into payer coverage and market adoption.
Related topics